Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As Executive Director, AI/ML Drug Discovery Analytics, you will be a senior leader shaping the future of data-driven drug discovery at Revolution Medicines. You will define the Research’s AI/ML strategy, oversee implementation of advanced analytics across discovery and build a world-class team to unlock the full potential of our rich internal datasets and make these insights accessible to other scientist. Your leadership will directly influence early discovery innovation, pipeline acceleration, and strategic portfolio decisions.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree
Number of Employees
251-500 employees